Diffuse Large B-Cell Lymphoma Cell Models for Research

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for approximately 30-40% of all cases. According to the World Health Organization (WHO), the global incidence of DLBCL is estimated at 150,000 new cases annually, with a mortality rate of about 50,000 per year. The disease is more common in older adults, with a median age at diagnosis of 66 years. Risk factors include immunosuppression, autoimmune diseases, and certain infections such as Epstein-Barr virus (EBV).

Despite advances in immunochemotherapy, such as R-CHOP, approximately 30-40% of patients relapse or have refractory disease. The 5-year overall survival rate varies by stage and risk factors: localized disease (stage I-II) has a 5-year survival of about 80%, while advanced disease (stage III-IV) drops to around 60%. The International Prognostic Index (IPI) and the revised IPI (R-IPI) are used to stratify patients. The high heterogeneity of DLBCL underscores the need for personalized therapeutic approaches and robust preclinical models.

DLBCL is an ideal model for mechanistic studies due to its well-characterized molecular subtypes, including germinal center B-cell (GCB) and activated B-cell (ABC) subtypes, which have distinct oncogenic dependencies. Public datasets such as TCGA and GEO provide extensive genomic, transcriptomic, and clinical data, enabling researchers to identify novel drivers and therapeutic targets. Open questions include the role of epigenetic dysregulation, tumor microenvironment interactions, and mechanisms of resistance to targeted therapies. Gene-edited cell models are essential for functional validation of these findings, allowing precise manipulation of genes in relevant cellular contexts.

DLBCL pathogenesis involves several key pathways:

1. B-cell receptor (BCR) signaling: Chronic active BCR signaling is a hallmark of the ABC subtype, driven by mutations in CD79A/CD79B and MYD88.

2. NF-κB pathway: Constitutive activation of NF-κB promotes survival and proliferation, often due to mutations in MYD88, CARD11, or TNFAIP3.

3. Apoptosis regulation: Mutations in TP53 and BCL2/BCL6 translocations impair apoptosis, leading to cell accumulation.

4. Epigenetic regulation: Mutations in histone modifiers (e.g., EZH2, KMT2D) and chromatin remodelers (e.g., CREBBP, EP300) alter gene expression programs.

Data from TCGA and COSMIC.

Key signaling networks in DLBCL include:

• • BCR signaling: Components include SYK, BTK, PLCγ2, PKCβ, and NF-κB.
• • NF-κB pathway: Involves IKK complex, IκBα, p65/p50, and downstream targets like BCL2, MYC, and cyclin D.
• • PI3K/AKT/mTOR pathway: Activated by BCR signaling and mutations in PIK3CA/PTEN.
• • JAK/STAT pathway: Often activated by IL-6/IL-10 autocrine loops.
• • MAPK pathway: RAS/RAF/MEK/ERK cascade, activated by mutations in KRAS/NRAS or upstream signaling.

These pathways are interconnected and provide multiple therapeutic targets.

Organoid models are emerging as more physiologically relevant systems, allowing co-culture with stromal cells and immune cells, but they are less established for DLBCL compared to solid tumors.

• • Patient-derived xenografts (PDX): Implantation of patient tumor cells into immunodeficient mice; preserves tumor heterogeneity but lacks immune system.
• • Genetically engineered mouse models (GEMM): Conditional knock-in of MYD88 L265P or BCL2 overexpression in B cells; recapitulates DLBCL features but is time-consuming.
• • Induced models: Use of viral vectors or CRISPR to introduce mutations in human cell lines followed by transplantation; faster but less faithful.
• • Syngeneic models: Mouse lymphoma cell lines (e.g., A20) in immunocompetent mice; useful for immunotherapy studies.

CRISPR-Cas9 technology enables the generation of isogenic cell lines with precise genetic modifications, such as:

• • Knockout (KO) lines: Disruption of tumor suppressor genes (e.g., TP53, PTEN) to study loss-of-function effects.
• • Knock-in (KI) lines: Introduction of oncogenic point mutations (e.g., MYD88 L265P, CD79B Y196) to model driver events.
• • Reporter lines: Fusion of fluorescent proteins (e.g., GFP) to endogenous genes to track protein expression or localization.

These models are commercially available from various sources, with sequence verification and quality control. They are essential for functional validation, drug screening, and mechanistic studies. For example, an isogenic pair of OCI-LY1 with and without TP53 knockout can be used to assess the impact of TP53 loss on drug sensitivity.

Gene-edited cell lines are used to validate candidate driver genes identified from genomic studies. For instance:

• • Knockout of MYD88 in ABC DLBCL lines (e.g., TMD8) reduces NF-κB activity and cell proliferation, confirming its oncogenic role.
• • Knock-in of EZH2 Y641 mutation in GCB lines enhances H3K27me3 levels and alters gene expression, supporting its role in lymphomagenesis.
• • CRISPR screens using pooled libraries can identify genes essential for cell survival, providing new therapeutic targets.

Isogenic cell line pairs (e.g., wild-type vs. knockout) are powerful tools for drug screening:

• • They allow identification of on-target vs. off-target effects.
• • Resistance mechanisms can be studied by exposing cells to increasing drug concentrations and analyzing genomic changes.
• • For example, BTK inhibitors (e.g., ibrutinib) are effective in ABC DLBCL; resistant lines can be generated to identify bypass signaling pathways.

CRISPR synthetic lethality screens can identify vulnerabilities in DLBCL cells with specific mutations. For example:

• • In MYD88-mutant cells, targeting IRAK4 or BTK may be synthetically lethal.
• • In TP53-mutant cells, targeting G2/M checkpoint kinases (e.g., WEE1) may be selectively toxic.
• • Gene-edited models can also be used to validate biomarkers for patient stratification.